| Status | Suspended |
| Process | STA pre-2018 |
| ID number | 389 |
| Referral date | 01 December 2007 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
| 2nd appraisal committee meeting | TBC |
Project Team
| Assessment Group / Evidence Review Group: | TBC |
| Communications manager: | Alice Law |
| Executive Lead: | Andrew Dillon |
| Project manager: | TBC |
| Technical Lead: | Andres Roman |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 June 2009 |
The manufacturer of capecitabine has advised us that they have not applied for regulatory approval in relation to this product at this time. The Institute has therefore decided to remove this appraisal from its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance